IPHA

MKT CAP:$167M

Innate Pharma

Market Cap

$167M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.71-$0.11 (-6.04%)

Jun 5, 2026

52W High $2.3852W Low $1.17

Company Details

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clini...

CEO

—

IPO Date

Oct 17, 2019

Website

www.innate-pharma.com

Key Metrics TTM (EUR)

Revenue

€990.0K

-98.4% YoY

Net Income

-€101M

EPS (Diluted)

Free Cash Flow

-€91M

Revenue / Share

€0.01

Gross Margin

5109.7%

Operating Margin

-10776.3%

Net Margin

-10232.8%

FCF Margin

-9202.2%

P/S

P/E

Earnings Reports

Q2 2026

Sep 17, 2026

PENDING

Q1 2026

May 13, 2026

-€2M-851.1%

FY 2025

Mar 26, 2026

€3M-77.9%

Q4 2025

Mar 26, 2026

-€2M

Q2 2025

Sep 17, 2025

€5M-60.6%

Revenue & Profitability (EUR)

Operating Cash Flow (EUR)

CapEx Spend (EUR)

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation (EUR)

OpEx Breakdown (EUR)

War Chest (EUR)

Shares Outstanding

Revenue Per Employee (EUR)

Revenue / Employee